Clinia Health Inc. advances to third round of Creative Destruction Lab’s AI program
Written by Clinia
MONTREAL, QC, December 16 – Clinia Health Inc. is proud to announce their advancement to the third round of the prestigious Creative Destruction Lab’s Artificial Intelligence program. The Montreal-based startup, which developed a proprietary search engine for the health ecosystem, will be working with some of the brightest minds in technology through this innovative program.
Companies advancing to the third round of the CDL AI stream will benefit from 1:1 mentorships with successful entrepreneurs who have built, managed and successfully exited multiple technology companies. Clinia plans to leverage this opportunity to obtain proven strategic advice from experts to scale its technology and contribute to the optimization of healthcare systems across the country and abroad by linking patients to the right healthcare providers at the right time. Their most recent partnership provided Canadians with the ability to quickly locate COVID-19 testing and screening locations directly within Waze, the GPS navigation app.
Launched in 2016, Clinia is changing the landscape of digital healthcare technology with its proprietary search infrastructure. Their unique approach to simplifying healthcare navigation provides users with curated, reliable and up-to-date information on available nearby healthcare resources. According to McKinsey’s landmark June 2020 Telehealth study, up to $250 billion of current US healthcare spend could potentially be virtualized, and Clinia aims to capitalize on this opportunity to simplify and streamline access to better care resources.
“Healthcare systems everywhere are overburdened, and our solutions were created to alleviate this strain by optimizing the patient journey and reducing the time and cost associated with case management and delivery of care, not just at home, but around the globe,” says Simon Bédard, CEO and co-founder of Clinia. “We’re immensely proud of the progress we’ve made toward our goals. Following in the footsteps of previous CDL cohorts and working with these proven technology leaders to accelerate our growth and bring our products to even more markets is something we look forward to in 2021.”
About Creative Destruction Lab
Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success.
Founded in 2012 by Professor Ajay Agrawal at the University of Toronto’s Rotman School of Management, the program has expanded to nine sites across four countries: Oxford (Saïd Business School, University of Oxford), Paris (HEC Paris), Atlanta (Scheller College of Business, Georgia Institute of Technology), Madison (Wisconsin School of Business, University of Wisconsin-Madison), Vancouver (Sauder School of Business, University of British Columbia), Montreal (HEC Montréal), Calgary (Haskayne School of Business, University of Calgary), and Halifax (Rowe School of Business, Dalhousie University).
Since its inception, companies that have participated in the CDL program have created more than $7.5 billion (CAD) in equity value. CDL alumni include North (Waterloo), Atomwise (San Francisco), Kyndi (Palo Alto), Xanadu (Toronto), BenchSci (Toronto), Kheiron Medical (London), and Roadbotics (Pittsburgh).
Clinia Health Inc. is a leader in the management, indexation and search of interoperable data within the healthcare space. Our health navigation platform connects thousands of establishments and providers in one comprehensive healthcare search experience. Using Clinia’s scalable technology, companies and health organizations of all sizes can build and customize search experiences within their own products to facilitate access to healthcare resources for their users. Our mission is to optimize healthcare navigation and simplify access to the right resources at the right time for our users.